Video

Part 1: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML

Author(s):

Alexandra S. Wolff, PharmD, BCOP, FHOPA

Alexandra S. Wolff, PharmD, BCOP, discusses use of IDH1 and IDH2 inhibitors in newly diagnosed AML patients and highlights recently released trial data.

Related Videos
Related Content
CAR T cell therapy in leukemia -- Image credit: LASZLO | stock.adobe.com
April 23rd 2025

Introducing Obecabtagene Autoleucel: A New Chapter in ALL Treatment

Amir Ali, PharmD, BCOP Tammy Harutunyan, PharmD Candidate Arman Melikyan, PharmD Candidate
The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma
January 31st 2025

The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor
3D rendering of thrombosis in an artery | Image Credit: © Matthieu - stock.adobe.com
April 22nd 2025

Thrombosis May Increase Risk of Cardiovascular Disease, Secondary Cancers in Myeloproliferative Neoplasms

Alexandra Gerlach, Associate Editor
Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap
January 29th 2024

Pharmacy Focus Oncology: Advancements in Hematology and Breast Cancer - ASH and SABCS 2023 Recap

Red blood cells | Image Credit: © digitalpochi - stock.adobe.com
April 18th 2025

Momelotinib Shows Strong Efficacy in JAK-Exposed Myelofibrosis Patients

Alexandra Gerlach, Associate Editor
Cancer cells in the blood stream | Image Credit: © freshidea - stock.adobe.com
April 17th 2025

Zanubrutinib Plus Venetoclax and Obinutuzumab Yields Deep Remissions in Patients With Chronic Lymphocytic Leukemia

Alexandra Gerlach, Associate Editor